Biotech Startups

Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options. It focuses on shifting care toward prevention rather than management of bleeds.

5 investors

Hilltop Bio develops regenerative biologic therapies for veterinary medicine, using its proprietary BioStabyl process to preserve biological components such as exosomes, extracellular matrix proteins, and growth factors. Its products are used by veterinarians to manage soft tissue injuries and support post-surgical recovery in small animals and equine patients.

5 investors

Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.

5 investors

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases. The company uses its proprietary SEQ SIFTER™ platform to develop first-in-class therapeutic antibodies targeting allergic cascades.

5 investors

Inceptive builds foundation models of biological systems for drug discovery, specializing in sequence-based medicines like mRNA and peptides. The company combines deep learning trained on heterogeneous life data with in-house wet lab validation to design novel drug candidates that outperform existing options.

5 investors

Inductive Bio builds AI and machine learning software to accelerate drug discovery for pharmaceutical and biotech researchers, combining computational chemistry with expertise in translating complex drug programs from preclinical to clinical stages.

5 investors

Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.

5 investors

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

5 investors

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

5 investors

Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases. The page presents investor relations content including financial results and corporate governance updates.

5 investors

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.

5 investors

Izote is a fermentation technology company developing an anaerobic process for industrial biomanufacturing. Its system offers predictable performance scaling, extended fermentation runs, and the use of low-cost bioreactors.

5 investors

Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications. The company runs an Investigator-Initiated Studies grants program to support independent research on diagnostic testing outcomes, health economics, and fundamental science related to its sequencing technology.

5 investors

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation. The company is advancing toward clinical trials.

5 investors

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

5 investors

LambdaVision develops a protein-based artificial retina designed to restore vision for patients blinded by advanced retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. The implant uses proteins similar to the visual pigment rhodopsin to mimic the light-absorbing function of damaged photoreceptor cells, and its manufacturing leverages space-based production.

5 investors

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

5 investors

Latch builds data infrastructure and software tools for biological computing, enabling researchers to program and automate biological discovery through high-throughput laboratory automation and machine learning.

5 investors

Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale. It serves therapeutics discovery and development, including antibody, cell therapy, immunotherapy, and regenerative medicine research.

5 investors

LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors. The company develops a general-purpose platform designed to accelerate the scientific method by enabling systems to learn independently rather than relying on hard-coded expert knowledge.

5 investors

Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease. Its lead drug candidate, LOY-002, is a once-daily pill for senior dogs that addresses metabolic dysfunction and is progressing through FDA conditional approval, alongside a broader portfolio of aging therapeutics and educational resources for veterinarians.

5 investors

Lycos PBC develops investigational psychedelic-based therapeutics to treat mental health conditions, with an initial focus on post-traumatic stress disorder. The company applies decades of evidence-based research to create new therapeutic approaches for patients with unmet mental healthcare needs.

5 investors

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network. The site serves as a landing page directing visitors to the two separate pharmaceutical companies.

5 investors

Manas AI is an AI-native biopharmaceutical company that uses neuro-symbolic foundational models to discover and develop medicines. The company serves the pharmaceutical industry with AI-driven drug discovery and development.

5 investors